<DOC DOCNO="nw/wsj/04/wsj_0463@0463@wsj@nw@en@on">
<ENAMEX TYPE="ORG">Genentech Inc.</ENAMEX> said the West German distributor of its heart drug TPA reached a joint marketing agreement with a subsidiary of <ENAMEX TYPE="ORG">Hoechst AG</ENAMEX> , which makes the rival anti-clotting agent streptokinase .
The biotechnology concern said the agreement between its longtime <ENAMEX TYPE="NORP">West German</ENAMEX> distributor , <ENAMEX TYPE="ORG">Boehringer - Ingleheim 's</ENAMEX> <ENAMEX TYPE="ORG">Dr. Karl Thomae G.m.b.H.</ENAMEX> subsidiary , and <ENAMEX TYPE="ORG">Hoechst</ENAMEX> 's <ENAMEX TYPE="ORG">Behringwerke</ENAMEX> subsidiary was an attempt to expand the market for blood - clot drugs in general .
A <ENAMEX TYPE="ORG">Genentech</ENAMEX> spokeswoman said the agreement calls for <ENAMEX TYPE="ORG">Hoechst</ENAMEX> to promote TPA for heart patients and streptokinase for other clot - reducing purposes .
</DOC>
